Stoke Therapeutics' Zorevunersen Shows Disease-Modifying Potential in Dravet Syndrome
Event summary
- Stoke Therapeutics published Phase 1/2a and open-label extension study results for zorevunersen in The New England Journal of Medicine, demonstrating potential disease modification in Dravet syndrome.
- The studies showed substantial and durable reductions in seizures and improvements in cognition and behavior over three years of treatment.
- Zorevunersen was generally well tolerated, with the most common adverse event being cerebrospinal fluid protein elevations.
- The Phase 3 EMPEROR study is expected to complete enrollment in Q2 2026, with a data readout on track for mid-2027.
The big picture
The publication of these data marks a significant milestone in the treatment of Dravet syndrome, a severe developmental and epileptic encephalopathy with no currently approved disease-modifying therapies. Stoke Therapeutics' RNA medicine approach targets the underlying genetic cause of the disease, potentially transforming the treatment landscape. The strategic collaboration with Biogen underscores the industry's growing interest in addressing rare, devastating neurological disorders through innovative mechanisms.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 EMPEROR study results will support a successful New Drug Application submission to the FDA in mid-2027.
- Commercialization Strategy
- How Stoke Therapeutics and Biogen will position zorevunersen in the market given the lack of approved disease-modifying therapies for Dravet syndrome.
- Long-term Efficacy
- The durability of the observed improvements in cognition and behavior beyond the three-year treatment period in the open-label extension studies.
Related topics